HoldsUp

DavidPerlmutterMD · 2021-05-03 · David Perlmutter (host), Robert H. Lustig

Take Back Your Health - with Dr. Robert H. Lustig | The Empowering Neurologist EP. 122

49 research-tied claims examined: 7 contradicted 7 overstated 7 context 20 supported 8 unverified

7

Overstated

0:16:45Robert H. Lustigoverstatedmoderate

Approximately 25% of all children in the United States have non-alcoholic fatty liver disease.

"and in fact 25% of the entire pediatric population of the United States have fatty liver." (said at 0:16:45)

The ~25% prevalence figure comes from recent National Health and Nutrition Examination Survey (NHANES 2017–2020) data evaluating US adolescents (ages 12–19) using transient elastography (controlled attenuation parameter), which identified a non-alcoholic fatty liver disease (NAFLD) prevalence of 25.8% (and metabolic dysfunction-associated steatotic liver disease [MASLD] prevalence of 20–23%). However, applying this figure to the 'entire pediatric population' overstates the prevalence across all childhood ages, as fatty liver disease is significantly less common in younger children, yielding an overall pediatric prevalence estimated at roughly 7% to 10% in general populations.

0:45:03Robert H. Lustigoverstatedmoderate

Twenty-five percent of children have fatty liver disease when evaluated by MRI.

"and 25% of kids, if you stick them in an MRI scanner, have fatty liver disease." (said at 0:45:03)

Large systematic reviews and meta-analyses show that the prevalence of non-alcoholic fatty liver disease (NAFLD / MASLD) in the general pediatric population is approximately 7% to 14%, not 25%. While hepatic steatosis prevalence reaches 38% to 41% among children with overweight or obesity, and adult global prevalence is approximately 25% to 30%, stating that 25% of children in general have fatty liver disease overstates general pediatric rates.

0:42:57Robert H. Lustigoverstatedmoderate

Healthcare spending in the United States totals 3.6 trillion dollars annually, with 75% of that spending directed toward chronic metabolic diseases.

"medical care in this country costs 3.6 trillion dollars a year, and of that, 75% are all these chronic metabolic diseases that we've been talking about." (said at 0:42:57)

Official National Health Expenditure Accounts data from the Centers for Medicare & Medicaid Services reported total US healthcare spending at $3.6 trillion in 2018. While public health literature and the CDC frequently estimate that roughly 75% to 90% of US healthcare expenditures are driven by chronic diseases and conditions broadly, attributing this entire 75% share specifically to 'chronic metabolic diseases' is an overstatement. The broad chronic disease category encompasses a wide range of non-metabolic conditions, including musculoskeletal disorders, mental health disorders, cancers, dementia, and chronic respiratory diseases.

1:01:10Robert H. Lustigoverstatedhigh

Homocysteine drives cardiovascular smooth muscle proliferation and leads to heart attacks.

"So homocysteine is a driver of cardiovascular smooth muscle proliferation. It is one of the things that leads to heart attacks." (said at 1:01:10)

Preclinical and mechanistic studies confirm that elevated homocysteine promotes vascular smooth muscle cell (VSMC) proliferation, migration, and phenotypic switching in vitro and in animal models. Furthermore, observational epidemiology shows an association between hyperhomocysteinemia and cardiovascular risk. However, the claim that homocysteine directly leads to heart attacks is overstated. High-certainty evidence from large-scale randomized controlled trials and a Cochrane systematic review involving over 46,000 participants shows that lowering plasma homocysteine levels with B-vitamin supplementation (folic acid, B6, and B12) does not reduce the incidence of myocardial infarction (RR 1.02, 95% CI 0.95 to 1.10) or all-cause mortality, indicating that homocysteine is a marker or correlated risk factor rather than an independent causal driver of heart attacks in humans.

1:03:12Robert H. Lustigoverstatedmoderate

Only 28% of US medical schools have a nutrition curriculum.

"Well, only 28% of medical schools even have a nutrition curriculum, and there's no CMEs for nutrition, except some rare things like integrative medicine at University of Arizona" (said at 1:03:12)

The cited figure appears to conflate national survey findings on medical school nutrition education. In a national survey of accredited U.S. medical schools by Adams et al. (2010), 94.5% (103/109) of responding schools required some form of nutrition education, typically integrated into other courses. However, only 25% (26/105) required a dedicated, standalone nutrition course, and only 27% (28/105) met the National Academy of Sciences recommendation of at least 25 total hours of nutrition instruction. While nutrition training in medical schools remains limited, claiming that only 28% have any nutrition curriculum misrepresents the data.

1:06:15Robert H. Lustigoverstatedhigh

Following the Master Settlement Agreement, cigarette consumption in America decreased by more than half.

"and now we have the Master Settlement Agreement and we have something at least to change cigarette consumption in America, and it did go down, you know, it got cut in more than half after that." (said at 1:06:15)

While the 1998 Master Settlement Agreement (MSA) led to price increases and reductions in smoking rates and overall cigarette consumption, claiming that consumption was 'cut in more than half after that' significantly overstates the impact. Econometric evaluations of nationwide population data following the settlement found much more modest declines: by 2002, the MSA was estimated to have reduced overall smoking rates by 5% among adults aged 21 to 64, and by 13% among young adults (ages 18–20) and seniors (65+).

1:08:20Robert H. Lustigoverstatedvery low

Short-chain fatty acids suppress the immune system and inhibit the cytokine storm caused by COVID-19, reducing mortality.

"Turns out those short-chain fatty acids are immunosuppressive and keep the cytokine storm that the virus generates at a low ebb, and so that will keep you from succumbing to massive cytokine storm from being so sick with COVID. So that will reduce mortality rates." (said at 1:08:20)

The claim is overstated. Published mechanistic and observational studies show that short-chain fatty acids (SCFAs, such as butyrate) possess immunomodulatory and anti-inflammatory properties that can dampen cytokine production and lung inflammation via the gut-lung axis. Furthermore, observational data correlate higher levels of SCFA-producing gut bacteria with milder COVID-19 severity and lower population-level mortality. However, stating definitively that SCFAs suppress the cytokine storm in COVID-19 to reduce clinical mortality overstates the evidence, as this reflects hypotheses, preclinical mechanistic models, and observational correlations rather than proven clinical trial outcomes in humans.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.